Ivacaftor (Kalydeco®) for the treatment of CF patients with the R117H mutation.
Kalydeco® for the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.
Rapid Review
| Commenced | Completed | Outcome |
| 14/01/2016 | 10/02/2016 | Full Pharmacoeconomic Evaluation Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 15/04/2016 | 05/01/2017 | Reimbursement Not Recommended at the Submitted Price |
The HSE has approved reimbursement following confidential price negotiations.